Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894179 · ClinicalTrials.gov registry record · NA
Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD
A NA study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT00894179 is a NA study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 45 participants.
The verdict
NCT00894179, a NA study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
Purpose: The investigators plan to test a newly FDA approved pharmacologic stress agent, Regadenoson, in conjunction with atropine in the use of stress echocardiography for the diagnosis of coronary artery disease. The selective nature of Regadenoson allows for its use in patients with contraindications to the currently used drug, Adenosine, which is non-selective. Furthermore, the proposed protocol can be completed faster and without radiation exposure than the current protocol with adenosine. Design: This is a prospective study evaluating people with no prior diagnosis of coronary disease with a prior stress test and are scheduled for cardiac catheterization. Patients who meet inclusion criteria will undergo regadenoson-atropine echocardiography protocol prior to their catheterization. The study will be interpreted by two independent readers blinded to the catheterization results. The sensitivity, specificity, positive and negative predictive values of the regadenoson-atropine study will be then be calculated using the coronary angiogram as a gold standard.
Interventions
- DIAGNOSTIC_TEST regadenoson and atropine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00894179
The ClinicalTrials.gov registry entry for NCT00894179 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which regadenoson and atropine is the first listed.
NCT00894179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00894179 about?
NCT00894179 is a clinical study titled "Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD". Purpose: The investigators plan to test a newly FDA approved pharmacologic stress agent, Regadenoson, in conjunction with atropine in the use of stress echocardiography for the diagnosis of coronary artery disease. The selective nature of Regadenoson allows for its use in patients with contraindicat...
What is the current status of trial NCT00894179?
This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2009-10. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00894179?
The interventions under investigation include: regadenoson and atropine (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00894179?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.